Archive · 26 May 2025
Aurobindo Pharma Reports Mixed Financial Results for Q4FY25
Imagine a company, Aurobindo Pharma, that makes medicines.
They just announced how well they did financially in the last few months (Q4) and the whole year (FY25).
In the last few months, they made a little less profit, but their sales went up.
Overall, for the whole year, they made more money than last year!
They sold more medicines too.
Sales in the US and Europe were strong.
While the growth market sales slowed a bit in the last quarter.
The company is also working to increase how much they can produce in Europe, aiming to make a lot of money there.
Aurobindo Pharma's consolidated net profit slightly decreased by 0.5% in Q4FY25.
The company's revenue from operations increased by 10.6% in Q4FY25.
For FY25, net profit rose nearly 10% and consolidated revenue from operations grew by 9.4%.
Formulations revenue grew by 12.2% in FY25.
Growth markets revenues declined nearly 8% in Q4FY25.
- Who
- Aurobindo Pharma is the subject.
- What
- Aurobindo Pharma's financial results for Q4FY25 and FY25 were released.
- When
- The financial data covers Q4FY25 (ended March 31, 2025) and the fiscal year 2024-25 (FY25).
- Where
- The company's performance spans across its global operations.
- Why
- The report details the company's performance and growth.
- Q4FY25 Net Profit
- Rs 903 crore
- Q4FY24 Net Profit
- Rs 907 crore
- Q4FY25 Revenue from Operations
- Rs 8,382 crore
- FY25 Net Profit
- Rs 3,484 crore
- FY24 Net Profit
- Rs 3,169 crore
- FY25 Revenue from Operations
- Rs 31,724 crore